Health
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
PRINCETON, N.J., March 28, 2026--Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy.
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/a50e75b48fe2eccaea6d2ac1f8f1452f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QC3FUZF2UKv3dV5eAAoFxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMg--/https://media.zenfs.com/en/business-wire.com/a50e75b48fe2eccaea6d2ac1f8f1452f","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/m9bMBKLrt_lsXl1AP8W46A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA-/https://media.zenfs.com/en/business-wire.com/a50e75b48fe2eccaea6d2ac1f8f1452f","width":1200,"height":165}},"lazy":false},{"type":"text","content":"High treatment completion and no discontinuations due to lack of efficacy observed across faster and slower switch strategies","length":125,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., March 28, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy (xanomeline and trospium chloride) when switching adult outpatients with schizophrenia from an oral atypical antipsychotic to Cobenfy monotherapy. Through 8 weeks, patients remained stable with mean Positive and Negative Syndrome Scale (PANSS) total scores remaining below baseline, and no new safety signals were observed, regardless of cross-titration duration. These findings provide important evidence to help inform treatment switch strategies in clinical practice. Data were presented at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) taking place March 25-29 in Florence, Italy.","length":825,"tagName":"p"},{"type":"text","content":""While transitioning patients is common in schizophrenia, clinicians have historically had limited data to help guide these decisions, especially for differentiated treatments like Cobenfy," said David Walling, PhD, principal investigator and chief clinical officer at Cenexel – CNS. "The data presented today provide much-needed insight into what happens during a switch to Cobenfy, notably that patients remained stable through 8 weeks of treatment regardless of a slower or faster cross-titration, which will help healthcare professionals make informed ...